Thus, utilization of the gp130Y757F model of GC, in which IL-11 has a major role in GC formation [15], allowed for a unique opportunity to explore whether markers of tumor regression following treatment could be detected within the serum proteome. The gene discussed is IL11; the disease is gastric cancer.